Document Detail


Arsenic trioxide inhibits osteosarcoma cell invasiveness via MAPK signaling pathway.
MedLine Citation:
PMID:  20592496     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Arsenic trioxide (As(2)O(3)) is an active ingredient in traditional Chinese medicine. Recent studies showed that it causes apoptosis in several cancer cells. However, research of As(2)O(3) in osteosarcoma is sparse. In our present study, an inhibitory effect of As(2)O(3) on osteosarcoma cell adhesion and metastasis was observed with a cell adhesion, migration and invasion test. The impact of As(2)O(3) on the activities of MMP-9 and MAPK pathway-related downstream factors was analyzed by western blotting. Our results showed that As(2)O(3) significantly inhibited motility, migration and invasion in HOS and MNNG cells in a concentration-dependent manner at concentrations ranging from 0.5-2 μM, and led to cytoskeletal rearrangements. As(2)O(3) exerted an inhibitory effect on the phosphorylation of ERK1/2 and MEK, which are the members of the MAPK family. Additionally, treatment with As(2)O(3) in combination with inhibitors specific for MEK (U0126) in HOS and MNNG cells resulted in a marked inhibition of cell invasion and As(2)O(3) could significantly reduce PMA-induced invasion. In conclusion, we demonstrate the inhibitory effects of As(2)O(3) on the invasiveness of HOS and MNNG cells, which may be due at least partly to inactivation of the MAPK signaling pathway.
Authors:
Ren Tingting; Guo Wei; Peng Changliang; Lu Xinchang; Yang Yi
Related Documents :
9377226 - Apoptotic cell nuclei favour aggregation and fluorescence quenching of dna dyes.
18304466 - Effect of all-trans retinoic acid on drug sensitivity and expression of survivin in lov...
21337486 - Electron transfer between genetically modified hansenula polymorpha yeast cells and ele...
21209026 - Rice brittle culm 6 encodes a dominant-negative form of cesa protein that perturbs cell...
17015706 - Establishment of lymphotoxin beta receptor signaling-dependent cell lines with follicul...
11371226 - Renal angiomyolipoma: further immunophenotypic characterization of an expanding morphol...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-07
Journal Detail:
Title:  Cancer biology & therapy     Volume:  10     ISSN:  1555-8576     ISO Abbreviation:  Cancer Biol. Ther.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-11-03     Completed Date:  2011-04-07     Revised Date:  2013-02-05    
Medline Journal Info:
Nlm Unique ID:  101137842     Medline TA:  Cancer Biol Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  251-7     Citation Subset:  IM    
Affiliation:
Musculoskeletal Tumor Center, Peking University People's Hospital, Beijing, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Arsenicals / pharmacology*
Bone Neoplasms / drug therapy*,  enzymology*,  pathology
Cell Adhesion / drug effects
Cell Line, Tumor
Cell Movement / drug effects
Humans
MAP Kinase Signaling System / drug effects*
Matrix Metalloproteinase 9 / metabolism
Mice
Mice, Nude
Mitogen-Activated Protein Kinase 1 / antagonists & inhibitors,  metabolism
Mitogen-Activated Protein Kinase 3 / antagonists & inhibitors,  metabolism
Osteosarcoma / drug therapy*,  enzymology*,  pathology
Oxides / pharmacology*
Phosphorylation / drug effects
Chemical
Reg. No./Substance:
0/Arsenicals; 0/Oxides; 1327-53-3/arsenic trioxide; EC 2.7.11.24/Mitogen-Activated Protein Kinase 1; EC 2.7.11.24/Mitogen-Activated Protein Kinase 3; EC 3.4.24.35/Matrix Metalloproteinase 9

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Terminal differentiation of chronic myelogenous leukemia cells is induced by targeting of the MUC1-C...
Next Document:  Commentary: accurate medical student performance evaluations and professionalism assessment: "yes, w...